PREMERA | BLUE CROSS

An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY POLICY – 5.01.636

Chronic Hepatitis B Antiviral Therapy

Effective Date:	Nov. 1, 2023	RELATED MEDICAL POLICIES:
Last Revised:	Oct. 10, 2023	5.01.606 Hepatitis C Antiviral Therapy
Replaces:	N/A	

Select a hyperlink below to be directed to that section.

Clicking this icon returns you to the hyperlinks menu above.

Introduction

Hepatitis B is a vaccine-preventable liver infection that is caused by the hepatitis B virus (HBV). Most patients recover from the infection, but a small percentage goes on to develop chronic hepatitis B (CHB). This risk is higher in younger patients. In the early stage, the infection may show no symptoms or nonspecific symptoms such as fatigue. Later, the infection can have overlapping symptoms with liver disease as well as extrahepatic manifestations. The drugs used to treat hepatitis B include pegylated interferons and nucleoside/nucleotide analogs. The decision to initiate treatment is primarily based on the presence of cirrhosis, serum alanine aminotransferase (ALT) level, and the HBV DNA level. Other factors include malignancy and pregnancy. This policy describes the criteria when hepatitis B drugs may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

Drug	Medical Necessity
Baraclude (entecavir) oral	**Baraclude (entecavir) may be considered medically necessary for adult and pediatric individuals 2 years of age and older when the following criteria are met:** • Individual has a confirmed diagnosis of chronic HBV infection **AND** • Individual is ≥ 18 years of age (compensated or decompensated liver disease) **OR** • Individual is 2 to 17 years of age with compensated liver disease **AND** • Individual has had inadequate response or intolerance to generic entecavir **AND** • Individual does not have a co-infection with human immunodeficiency virus (HIV) **OR** • Individual has a co-infection with HIV and is receiving highly active antiretroviral therapy
Epivir-HBV (lamivudine) oral	**Epivir-HBV (lamivudine) oral solution may be considered medically necessary for adult and pediatric individuals 2 years of age and older when the following criteria are met:** • Individual has a confirmed diagnosis of chronic HBV infection **AND** • Individual has compensated liver disease **AND** • Documentation is provided that the oral solution is medically necessary (e.g., dosage is less than 100 mg daily, unable to swallow) **AND** • Individual does not have a co-infection with human immunodeficiency virus (HIV) **OR** • Individual has a co-infection with HIV and is receiving highly active antiretroviral therapy (HAART)

Drug	Medical Necessity
	Epivir-HBV (lamivudine) oral tablet may be considered medically necessary for adult and pediatric individuals 2 years of age and older when the following criteria are met: • Individual has a confirmed diagnosis of chronic HBV infection **AND** • Individual has compensated liver disease **AND** • Individual has had inadequate response or intolerance to generic lamivudine **AND** • Individual does not have a co-infection with human immunodeficiency virus (HIV) **OR** • Individual has a co-infection with HIV and is receiving highly active antiretroviral therapy (HAART)
Hepsera (adefovir dipivoxil) oral	**Hepsera (adefovir dipivoxil) may be considered medically necessary for adult and pediatric individuals 12 years of age and older when the following criteria are met:** • Individual has a confirmed diagnosis of chronic HBV infection **AND** • Individual is ≥ 18 years of age (compensated or decompensated liver disease) **OR** • Individual is 12 to 17 years of age with compensated liver disease **AND** • Individual has had inadequate response or intolerance to generic adefovir **AND** • Individual does not have a co-infection with human immunodeficiency virus (HIV) **OR** • Individual has a co-infection with HIV and is receiving highly active antiretroviral therapy (HAART)
Pegasys (peginterferon alfa-2a) SC	**Pegasys (peginterferon alfa-2a) may be considered medically necessary for the treatment of CHB in:**

Drug	Medical Necessity
	• Adult individuals with hepatitis B e-antigen (HBeAg) positive and HBeAg-negative CHB who have compensated liver disease and evidence of viral replication and liver inflammation **OR** • Non-cirrhotic pediatric individuals 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT)
Vemlidy (tenofovir alafenamide) oral	**Vemlidy (tenofovir alafenamide) may be considered medically necessary for adult and pediatric individuals 12 years of age and older when the following criteria are met:** • Individual has a confirmed diagnosis of chronic HBV infection **AND** • Individual has compensated liver disease **AND** • Individual does not have a co-infection with human immunodeficiency virus (HIV) **OR** • Individual has a co-infection with HIV and is receiving highly active antiretroviral therapy (HAART)

Drug	Investigational
As listed	**All other uses of the above-named agents when used for conditions not outlined in this policy or policy** 5.01.606 Hepatitis C Antiviral Therapy **are considered investigational.**

Length of Approval	
Approval	**Criteria**
Initial authorization	**Drugs listed in this policy may be approved up to 12 months.**
Re-authorization criteria	**Future re-authorization of drugs listed in this policy may be approved up to 12 months as long as the medical necessity criteria are met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy (e.g., a reduction in HBV DNA levels).**

Documentation Requirements

The individual's medical records submitted for review for all conditions should document that medical necessity criteria are met. The record should include the following:

- Office visit notes that contain the diagnosis, relevant history, physical evaluation, HBV DNA (viral load), and medication history

Coding

N/A

Related Information

Definition of Terms

Hepatitis B surface antigen (HBsAg): is found on the virus surface. All persons with HBsAg are infectious.

Hepatitis B e-antigen (HBeAg): is found in the inner core of the virus. All persons with positive HBeAg are most infectious.

Anti-Hepatitis B e-antigen (anti-HBe): antibodies to HBeAg, an indicator of resolution of acute infection.

HBV DNA: is a partially double-stranded DNA molecule found in the inner core of the virus. All persons with elevated HBV DNA are most infectious.

Chronic hepatitis B (CHB): HBsAg positive for at least 6 months; HBV DNA varies from undetectable to several billion IU/mL; persons can have HBeAg positive (typically associated with higher HBV DNA levels >20,000 IU/mL) and HBeAg negative (typically associated with lower HBV levels); ALT and/or ASL levels may be normal or elevated; liver biopsy results show chronic hepatitis with variable necroinflammation and/or fibrosis.

Immune-tolerant chronic hepatitis B: HBsAg present for at least 6 months; HBeAg positive; HBV DNA levels are very high (typically >1 million IU/mL); normal or minimally elevated ALT and/or AST; liver biopsy or noninvasive test results showing no fibrosis and minimal inflammation.

Immune-Active CHB: HBsAg present for at least 6 months; HBV DNA levels >20,000 IU/mL in HBeAg-positive CHB and >2,000 IU/mL in HBeAg-negative CHB; intermittently or persistently elevated ALT and/or AST levels; liver biopsy or noninvasive test results show CHB with moderate or severe necroinflammation and with or without fibrosis.

Inactive CHB: HBsAg present for at least 6 months; HBeAg negative and anti-HBe positive; HBV DNA levels <2,000 IU/mL; persistently normal ALT and/or AST levels; liver biopsy confirms absence of significant necroinflammation, and biopsy or noninvasive testing show variable levels of fibrosis.

HBeAg seroconversion: loss of HBeAg and detection of anti-HBe in a person who was previously HBeAg positive and anti-HBe negative.

Viral genotyping

There are 10 genotypes of HBV currently known, labeled A through J, with genotypes A, B, and C being most prevalent in the U.S. Infection or immunization with 1 genotype usually provides immunity to all genotypes.

Benefit Application

Baraclude (entecavir), Epivir-HBV (lamivudine), Hepsera (adefovir dipivoxil), Pegasys (peginterferon alfa-2a), and Vemlidy (tenofovir alafenamide) are managed through the Pharmacy benefit.

Evidence Review

Background

In 2015, the United States had approximately 2 million people with chronic hepatitis B with 847,000 people living with chronic HBV and 1.25 million people who were chronic HBV carriers. The prevalence rate was about 0.3%. Although the greatest incidence was in adults 30 to 39 years of age, infants and young children who were exposed to HBV had a greater chance of developing chronic hepatitis B. Non-Hispanic blacks had more than 2-fold higher rate of infection compared to other racial and ethnic populations in the U.S.

According to the AASLD 2018 Hepatitis B Guidance, preferred approved antiviral therapies for CHB treatment in adults and children include peg-interferon alpha-2a, entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide. Nonpreferred therapies include lamivudine, adefovir, and telbivudine.

Summary of Evidence

Coinfection with Hepatitis C Virus (HCV)

Direct-acting antiviral (DAA) HCV therapy has been reported to increase HBV DNA levels in HBsAg-positive individuals and elevate ALT levels concurrently with HBV reactivation. In HCV/HBV coinfected persons, HBV antiviral therapy should be started concurrently with DAA therapy. Entecavir, tenofovir disoproxil fumarate, or tenofovir alafenamide are preferred agents.

Coinfection with Human Immunodeficiency Virus (HIV)

The prevalence of HBV infection among HIV patients is 5-10% with the highest rate occurring in mem who have sex with men and IV drug users. Lamivudine, emtricitabine, and tenofovir are nucleoside analogues with activity against both HIV and HBV. However, due to resistance against lamivudine monotherapy, HIV/HBV-coinfected persons should receive two-drug antiretroviral therapy regimen.

Coinfection with Hepatitis Delta Virus (HDV)

Persons with HIV infection, persons who inject drugs, men who have sex with men, and immigrants from areas of high HDV endemicity with positive HBsAg should be tested for HDV.

Baraclude (entecavir)

Baraclude is a deoxyguanosine nucleoside analogue that inhibits HBV DNA synthesis via its activity against HBV reverse transcriptase.

The efficacy of Baraclude was evaluated in three phase 3 active-controlled trials. Study AI463022 compared Baraclude 0.5 mg once daily to lamivudine 100 mg once daily for 52 weeks in 709

nucleoside-inhibitor-naïve subjects with HBeAg-positive chronic HBV infection and compensated liver disease. Study AI463027 compared Baraclude 0.5mg to lamivudine 100mg once daily for 52 weeks in 638 nucleoside-inhibitor-naïve subjects with HBeAg-negative chronic HBV infection and compensated liver disease. The proportion of subjects who achieved undetectable HBV DNA (<300 copies/mL) was 67% and 90% in Baraclude-treated group in Study AI463022 and Study AIU463027, respectively, compared to 36% and 72% in lamivudine-treated groups. Study AI463026 evaluated the efficacy of Baraclude in lamivudine-refractory chronic HBV infection and compensated liver disease. Subjects either switched to Baraclude 1 mg once daily (no washout period, n=124) or continued on lamivudine 100 mg (n=116) for 52 weeks. At week 48, 19% of Baraclude-treated group achieved undetectable HBV DNA (<300 copies/mL) versus 1% of lamivudine-treated group.

Study AI463048 compared Baraclude 1 mg once daily (n=100) to adefovir dipivoxil 10 mg once daily (n=91) in adults with HBeAg-positive or HBeAg-negative chronic HBV infection and decompensated liver disease, defined as Child-Turcotte-Pugh score of 7 or higher. At week 48, 57% of Baraclude-treated individuals achieved undetectable HBV DNA while 20% of adefovir-treated individuals.

The efficacy and safety of Baraclude in the pediatric population was evaluated in Study AI463189 which included nucleoside-inhibitor-treatment-naïve subjects 2 to less than 18 years of age with HBeAg-positive chronic HBV infection, compensated liver disease, and elevated ALT. At week 48, 58% of treatment-naïve subjects and 47% of lamivudine-experienced subjects achieved HBV DNA <50 IU/mL. Individuals either received Baraclude 0.015 mg/kg up to 0.5 mg/day (n=120) or placebo (n=60). At week 48, 46% of Baraclude-treated group achieved HBV DNA <50 IU/mL compared to 2% in placebo-treated group.

Epivir-HBV (lamivudine)

Epivir-HBV is a nucleoside analogue reverse transcriptase inhibitor. Lamivudine is converted to an active metabolite that inhibits RNA- and DNA-dependent polymerase activities of HBV reverse transcriptase via DNA chain termination.

The safety of Epivir-HBV was evaluated in 3 clinical trials including subjects with CHB and compensated liver disease. Trial 1 compared Epivir-HBV 100 mg once daily (n=62) to placebo (n=63) in treatment-naïve U.S. subjects for 52 weeks followed by 16 weeks of no-treatment period. Trial 2 compared Epivir-HBV 25 mg once daily and Epivir-HBV 100 mg once daily (total n=131) to placebo (n=68) in Asian subjects for 52 weeks. Trial 3 compared Epivir-HBV 100 mg once daily in North American and European subjects for 52 weeks, followed by either Epivir-HBV

100 mg once daily (n=110) or placebo (n=54) for 16 weeks. At week 52, histologic response (defined as greater than or equal to 2-point decrease in the Knodell Histologic Activity Index compared to baseline) showed improvement in 55%, 56%, and 56% of Epivir-HBV-treated group in Trials 1, 2, and 3, respectively, compared to 25%, 26%, and 26% of placebo-treated group. The majority of Epivir-HBV treated individuals showed a decrease in HBV DNA levels to below the assay limit early in the course of therapy, but only one-third had undetectable HBV DNA levels after the initial response.

The safety and efficacy of Epivir-HBV in pediatric subjects were evaluated in a double-blind clinical trial including 286 subjects of 2 to 17 years of age with CHB and compensated liver disease. Individuals either received Epivir-HBV 3 mg/kg once daily up to 100 mg once daily or placebo. At week 52, 23% of Epivir-HBV-treated group and 13% of placebo-treated group achieved loss of HBeAg and undetectable HBV DNA. Adolescents aged 13 to 17 years showed less evidence of treatment effect than younger pediatric patients.

Hepsera (adefovir dipivoxil)

Hepsera is an acyclic nucleotide analog of adenosine monophosphate that is converted to adefovir diphosphate, which inhibits HBV DNA reverse transcriptase by causing DNA chain termination.

The efficacy of Hepsera was evaluated in two randomized, double-blind, placebo-controlled clinical trials in subjects with CHB (Study 437 and Study 438). At week 48, 53% and 64% of Hepsera-treated groups in Study 437 (n=168) and Study 438 (n=121), respectively, achieved histological improvement, defined as at least 2-point decrease in the Knodell necro-inflammatory score with no worsening of the Knodell fibrosis score, compared to 25% and 35% of placebo-treated groups. In Study 437, subjects who continued treatment with Hepsera to 72 weeks achieved maintenance of mean reductions in DBV DNA levels observed at week 48. In Study 438, subjects were re-randomized at week 48 to continue receiving Hepsera or placebo for an additional 48 weeks. At week 96, 71% of Hepsera-treated individuals had undetectable HBV DNA (<1000 copies/mL).

Study 518 evaluated the efficacy of Hepsera in pediatric individuals aged 2 to less than 18 years with CHB by comparing Hepsera (n=115) to placebo (n=58). In the age group of 12 to less than 18 years, 23% of Hepsera-treated group achieved HBV DNA levels <1000 copies/mL at week 48. The other age groups did not meet the primary endpoints with statistical significance.

The safety of Hepsera was evaluated using pooled data from Studies 437 and 438. At week 48, the most common adverse reactions reported in 3% or more of all Hepsera-treated subjects were asthenia, headache, abdominal pain, nausea, flatulence, diarrhea, and dyspepsia.

Pegasys (peginterferon alfa-2a)

Pegasys is a recombinant human interferon alfa-2a that binds to the human type 1 interferon receptor leading to receptor dimerization, activating transduction pathways mediated by JAK/STAT pathway. Pegasys has activity against both hepatitis B and C viruses.

The efficacy of Pegasys was evaluated in Study 8 (HBeAg-positive) and Study 9 (HBeAg-negative) individuals with CHB and compensated liver disease. In Study 8, subjects were randomized to receive Pegasys 180mcg SC once weekly (n=271) or lamivudine 100mg once daily (n=272). At week 48, 32% of Pegasys-treated group achieved HBV DNA <100,000 copies/mL compared to 62% of lamivudine-treated group. In Study 9, subjects were randomized to receive Pegasys 180mcg SQ once weekly (n=177) or lamivudine once daily (n=181). At week 48, 43% of Pegasys-treated group achieved HBV DNA <20,000 copies/mL compared to 85% of lamivudine-treated group.

Study 10 evaluated the efficacy of Pegasys in pediatric subjects aged 3 to less than 18 years with HBeAg-positive CHB in the immune-active phase and no cirrhosis. Individuals were randomized to receive Pegasys (n=101) or no treatment (n=50). At week 48, Pegasys-treated group had 34% achieve HBV DNA <20,000 IU/mL and 29% achieve HBV DNA <20,000 IU/mL, compared to 4% and 2% of the untreated group, respectively.

In Studies 8 and 9, the most common serious adverse reactions were infections, hepatitis B flares, and thrombotic thrombocytopenic purpura happening in <1% of subjects. Other non-serious common adverse events included pyrexia, headache, fatigue, myalgia, alopecia, and anorexia.

Vemlidy (tenofovir alafenamide)

Vemlidy is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor. Tenofovir alafenamide is a phosphonamidite prodrug of tenofovir, which is then converted to an active metabolite that incorporates into viral DNA reverse transcriptase, inhibiting HBV replication.

The efficacy of Vemlidy in the treatment of adults with CHB and compensated liver disease is based on 48-week data from 2 randomized, double-blind, active-controlled trials including both treatment-naïve and treatment-experienced adults. In trial 108, HBeAg-negative individuals either received Vemlidy 25 mg (n=285) once daily or tenofovir disoproxil fumarate (TDF) 300mg (n=140) once daily. In trial 110, HBeAg-positive individuals either received Vemlidy 25mg once daily (n=581) or TDF 300mg (n=292) once daily. The efficacy endpoint in both trials was the proportion of subjects with plasma HBV DNA levels below 29 IU/mL at week 48. In trial 108, 92% of Vemlidy-treated adults and 93% of TDF-treated adults achieved HBV DNA <29 IU/mL. The corresponding proportions in trial 110 were 63% and 67% in the Vemlidy-treated group and TDF-treated group, respectively.

The efficacy of switching from TDF to Vemlidy in virologically suppressed adults with CHB infection was evaluated in a 48-week, randomized, double-blind, active-controlled trial requiring subjects to have been taking TDF 300 mg once daily for at least 12 months with HBV DNA <20 IU/mL at screening. Individuals were then randomized to receive Vemlidy 25 mg once daily (n=243) or TDF 300mg once daily (n=245). The primary endpoint was the proportion of adults with plasma HBV DNA levels of ≥20 IU/mL at week 48. Both groups had <1% who achieved the primary endpoint.

Trial 4035 evaluated the efficacy and safety of switching from TDF and/or other antivirals to Vemlidy in an open-label study of adults with virological suppression and moderate to severe renal impairment (Cohort 1, n=78) or end-stage renal disease (ESRD) on hemodialysis (Cohort 2, n=15). At week 24, 98% of subjects achieved HBV DNA <20 IU/mL. There were no significant differences in mean change from baseline in ALT values and mean change in HBsAg level from baseline between these groups.

Trial 1092 was a randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of Vemlidy in subjects 12 to 18 years of age weighing at least 35 kg with CHB infection. Individuals either received Vemlidy (n=47) or placebo (n=23) once daily. At week 24, 21% of Vemlidy-treated group achieved HBV DNA <20 IU/mL versus 0% in placebo-treated group. ALT normalization (according to AASLD criteria) was achieved in 44% of Vemlidy-treated group and 0% in placebo-treated group.

The safety of Vemlidy was assessed based on pooled data of 1298 patients from Trial 108 and Trial 110 who continued treatment through week 120. Week 97 analysis showed that the most common adverse reactions reported in at least 10% of subjects was headache, similarly in both Vemlidy- and TDF-treated groups. Other adverse reactions reported in at least 5% of subjects included abdominal pain, cough, back pain, fatigue, nausea, arthralgia, diarrhea, and dyspepsia.

Practice Guidelines

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis guidance

The American Association for the Study of Liver Diseases (AASLD) approved this practice guidelines on December 4, 2017, to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic Hepatitis B. The 2018 update in available on the Internet at **https://www.aasld.org/practice-guidelines/chronic-hepatitis-b** and included (1) the use of tenofovir alafenamide; (2) guidance on screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coinfections, acute hepatitis B, recipients of immunosuppressive therapy, and transplant recipients.

References

1. Wright TL: Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006; 101 Suppl 1:S1-S6.
2. Abara WE, Qaseem A, Schillie S, et al: Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2017; 167(11):794-804.
3. Wright TL: Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006; 101 Suppl 1:S1-S6.
4. Schillie S , Vellozzi C , Reingold A , et al: Prevention of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67(1):1-31.
5. Haber BA, Block JM, Jonas MM, et al: Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. Pediatrics 2009; 124(5):e1007-e1013.
6. Centers for Disease Control and Prevention: Surveillance for acute viral Hepatitis - United States, 2007. MMWR Morb Mortal Wkly Rep 2009; 58(SS-3):1-27.
7. Koziel MJ & Peters MG: Viral hepatitis in HIV infection. N Engl J Med 2007; 356(14):1445-1454.
8. Vemlidy (tenofovir aladenamide) [prescribing information]. Gilead Sciences, Inc. Foster City, CA. Revised October 2022.
9. Epivir-HBV (lamivudine) [prescribing information]. GlaxoSmithKline. Research Triangle Park, NC. Revised December 2021.
10. Baraclude (entecavir) [prescribing information]. Bristol-Myers Squibb Company. Princeton, NJ. Revised November 2019.
11. Hepsera (adefovir dipivoxil) [prescribing information]. Gilead Sciences, Inc. Foster City, CA. Revised December 2018.
12. Pegasys (peginterferon alfa-2a) [prescribing information]. Genentech, Inc. South San Francisco, CA. Revised March 2021.
13. Terrault, Norah A.*; Lok, Anna S.F.; McMahon, Brian J.; Chang, Kyong-Mi; Hwang, Jessica P.; Jonas, Maureen M.; Brown, Robert S. Jr.; Bzowej, Natalie H.; Wong, John B.. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 67(4):p 1560-1599, April 2018. | DOI: 10.1002/hep.29800

14. Janssen HL, van Zonneveld M, Senturk H, et al; HBV 99-01 Study Group. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet. 2005; 365(9454):123-129.
15. Chan HL, Leung NW, Hui Ay et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005:142(4):240-250.
16. Lau GK, Piratvisuth T, Luo KX, et al; Peginterferon Alfa-2a HbeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine, and the combination for HbeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352(26):2682-2695.
17. Marcellin P, Lau GK, Bonino F, et al; Peginterferon Alfa-2a HbeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HbeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351(12):1206-1217.
18. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507-539.
19. Marcellin P, Brunetto M, Bonino F et al. In patients with HbeAg-negative chronic hepatitis B HbsAg serum levels early during treatment with peginterferon alfa-2° predict HbsAg clearance 4 years post-treatment [abstract]. The 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, MA. November 2-6, 2007.

History

Date	Comments
11/01/23	New policy, approved October 10, 2023, effective for dates of service on or after November 1, 2023. Add to Prescription Drug section. Added coverage criteria for Baraclude, Epivir-HBV, Hepsera, and Vemlidy for the treatment of chronic hepatitis B. Moved Pegasys (peginterferon alfa-2a) policy criteria for the treatment of chronic hepatitis B from 5.01.606 Hepatitis C Antiviral Therapy to 5.01.636 Chronic Hepatitis B Antiviral Therapy.

Discrimination is Against the Law

Premera Blue Cross (Premera) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. Premera provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). Premera provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that Premera has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator ─ Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-4535, Fax: 425-918-5592, TTY: 711, Email AppealsDepartmentInquiries@Premera.com. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 509F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html.

Washington residents: You can also file a civil rights complaint with the Washington State Office of the Insurance Commissioner, electronically through the Office of the Insurance Commissioner Complaint Portal available at https://www.insurance.wa.gov/file-complaint-or-check-your-complaint-status, or by phone at 800-562-6900, 360-586-0241 (TDD). Complaint forms are available at https://fortress.wa.gov/oic/onlineservices/cc/pub/complaintinformation.aspx.

Alaska residents: Contact the Alaska Division of Insurance via email at insurance@alaska.gov, or by phone at 907-269-7900 or 1-800-INSURAK (in-state, outside Anchorage).

Language Assistance

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 800-722-1471 (TTY: 711).

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 800-722-1471 (TTY: 711).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 800-722-1471 (TTY：711）。

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 800-722-1471 (TTY: 711).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 800-722-1471 (TTY: 711) 번으로 전화해 주십시오.

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 800-722-1471 (телетайп: 711).

LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 800-722-1471 (TTY: 711).

MO LOU SILAFIA: Afai e te tautala Gagana fa'a Sāmoa, o loo iai auaunaga fesoasoan, e fai fua e leai se totogi, mo oe, Telefoni mai: 800-722-1471 (TTY: 711).

ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັຽຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທຣ 800-722-1471 (TTY: 711).

注意事項：日本語を話される場合、無料の言語支援をご利用いただけます。800-722-1471 （TTY:711）まで、お電話にてご連絡ください。

PAKDAAR: Nu saritaem ti Ilocano, ti serbisyo para ti baddang ti lengguahe nga awanan bayadna, ket sidadaan para kenyam. Awagan ti 800-722-1471 (TTY: 711).

УВАГА! Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної підтримки. Телефонуйте за номером 800-722-1471 (телетайп: 711).

ប្រយ័ត្ន៖ បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតឈ្នួល គឺអាចមានសំរាប់បំរើអ្នក។ ចូរ ទូរស័ព្ទ 800-722-1471 (TTY: 711)។

ማስታወሻ: የሚናገሩት ቋንቋ ኣማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፣ በነጻ ሊያግዝዎት ተዘጋጀተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 800-722-1471 (መስማት ለተሳናቸው፡ 711).

XIYYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 800-722-1471 (TTY: 711).

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 800-722-1471 (رقم هاتف الصم والبكم: 711).

ਧਿਆਨ ਦਿਓ: ਜੇ ਤੁਸੀਂ ਪੰਜਾਬੀ ਬੋਲਦੇ ਹੋ, ਤਾਂ ਭਾਸ਼ਾ ਵਿੱਚ ਸਹਾਇਤਾ ਸੇਵਾ ਤੁਹਾਡੇ ਲਈ ਮੁਫਤ ਉਪਲਬਧ ਹੈ। 800-722-1471 (TTY: 711) 'ਤੇ ਕਾਲ ਕਰੋ।

เรียน: ถ้าคุณพูดภาษาไทยคุณสามารถใช้บริการช่วยเหลือทางภาษาได้ฟรี โทร 800-722-1471 (TTY: 711).

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 800-722-1471 (TTY: 711).

UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 800-722-1471 (TTY: 711).

ATANSYON: Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 800-722-1471 (TTY: 711).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 800-722-1471 (ATS : 711).

ATENÇÃO: Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 800-722-1471 (TTY: 711).

ATTENZIONE: In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 800-722-1471 (TTY: 711).

توجه: اگر به زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با 800-722-1471 (TTY: 711) تماس بگیرید.